Key result
White adipose tissue dysfunction drives cardiometabolic alterations in obesity via impaired expansion, hypertrophy, and inflammation.
Why the study?
Because not all individuals with excess adiposity develop comorbidities, simple tools are needed to identify white adipose tissue dysfunction and detect those at risk for metabolic alterations.
Highlights the need for simple tools to detect white adipose tissue dysfunction to identify individuals at risk for metabolic alterations despite excess adiposity.
Emerging tools to assess white adipose tissue function may identify high-risk obese patients; leaves open prospective validation before clinical adoption.
White adipose tissue (AT) dysfunction plays an important role in the development of cardiometabolic alterations associated with obesity. AT dysfunction is characterized by the loss of the expansion capacity of the AT, an increment in adipocyte hypertrophy, and changes in the secretion profile of adipose cells, associated with accumulation of macrophages and inflammation. Since not all people with an excess of adiposity develop comorbidities, it is necessary to find simple tools that can evidence AT dysfunction and allow the detection of those people with the potential to develop metabolic alterations. This review focuses on the current pathophysiological mechanisms of white AT dysfunction and emerging measurements to assess its functionality.
No takes yet. Share an insight, caveat, or question.
Santillana et al. (2023) conducted a review in White adipose tissue dysfunction and obesity. White adipose tissue dysfunction drives cardiometabolic alterations in obesity through impaired expansion, adipocyte hypertrophy, and inflammation, necessitating emerging tools to assess functionality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: